BioCryst Pharmaceuticals announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees stock options to purchase an aggregate of 16,050 shares, and restricted stock units covering an aggregate of 11,300 shares, of BioCryst common stock. The options and RSUs were granted as of February 29, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BCRX:
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New Regulation Risk for BioCryst Pharmaceuticals – What’s the Latest?
- BioCryst files automatic mixed securities shelf
- Biocryst Pharmaceuticals Enhances Report with Exhibit 99.1
- BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
